Contraception and fertility preservation counseling in reproductive-aged women diagnosed with nongynecologic cancer

Knight, Samantha; Ogburn, Joseph A Tony; Sokkary, Nancy

doi:10.1016/j.contraception.2014.05.175

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, one woman was still found to be using a hormonal-based contraceptive method during chemotherapy and while receiving long-term adjuvant treatment [ 35 ]. A retrospective chart review showed that 45% of women had documentation of contraceptive methods prior to initiation of treatment [ 40 ]. Lower use of effective tier I/II methods (27%) compared with tier III/IV (35%) methods following a cancer diagnosis was also reported in the USA [ 43 ].…”

Section: Resultsmentioning

confidence: 99%

Contraceptive use and contraceptive counselling interventions for women of reproductive age with cancer: a systematic review and meta-analysis

Harris

Feyissa

Gemzell‐Danielsson

et al. 2022

BMC Med

View full text Add to dashboard Cite

Background A lack of clarity exists regarding contraceptive uptake and counselling among women with cancer, despite these women having unique family planning needs. This study aimed to systematically review the available literature and produce an overall summary estimate of contraceptive use and counselling among women with cancer across the cancer care continuum. Methods A systematic search of articles reporting on contraceptive counselling and/or contraceptive use among women of reproductive age (15–49 years) with cancer across the cancer care continuum (e.g. diagnosis, treatment, survivorship) was conducted in MEDLINE, Embase, CINAHL, Maternity and Infant Care and Cochrane Library. Two independent reviewers conducted the data screening, data extraction and risk of bias assessment. Qualitative synthesis and meta-analyses were conducted to summarise the key findings. Results We included 21 articles involving 3835 participants in this review. Studies varied according to the cancer population and time along the cancer care continuum it was assessed. Of the studies that reported the overall contraceptive prevalence among women diagnosed with cancer (n = 8), contraceptive use ranged from 25 to 92%. Of the four studies that focused on cancer survivors, the contraceptive prevalence ranged from 47 to 84%. When the prevalence of these studies was pooled, a crude summary prevalence of 64% (62% among women with cancer versus 68% among cancer survivors) was found. The rate of contraceptive counselling was assessed in ten studies. A pooled prevalence of 50% (44% among women with cancer versus 58% among cancer survivors) was found, with the prevalence ranging from 12 to 78% among individual studies depending on the point in the cancer care continuum that it was provided. When contraceptive counselling was provided, it was found to significantly increase contraceptive use although biases were identified in its application. Conclusions Contraceptive counselling interventions as part of standard cancer care have the potential to not only empower women with cancer and cancer survivors to make informed choices regarding their reproductive health but also provide the ability to plan future pregnancies for times of better health.

show abstract

Section: Resultsmentioning

confidence: 99%